Skip to main content
Top
Published in: Current Geriatrics Reports 3/2013

01-09-2013 | Neurology of Aging (KS Marder, Section Editor)

Primary Central Nervous System Tumors in the Aging Population

Author: Fabio M. Iwamoto

Published in: Current Geriatrics Reports | Issue 3/2013

Login to get access

Abstract

The incidence of primary brain tumors peaks in the aging population, and advanced age in often a prognostic factor associated with shorter survival. In the United States, it is estimated that 69,720 individuals will be diagnosed with primary CNS tumors in 2013, of which 24,560 are expected to be malignant and 45,160 non-malignant. Approximately 50 % of primary CNS tumors are expected to occur in individuals who are 65 years or older. Management of elderly patients with primary brain tumors is challenging because there is no accepted standard of care treatment and this population may have multiple comorbidities, decreased tolerance to treatment, and increased risk for radiation-induced neurotoxicity. This review gives an overview of the treatment options for older patients with glioblastoma and meningioma, the most common primary brain tumors in this population. Treatment of elderly patients with primary brain tumors needs to be individualized, and old age alone should not preclude the use of life-prolonging treatments.
Literature
1.
go back to reference Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncology. 2012;14 Suppl 5:v1–v49.PubMedCrossRef Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncology. 2012;14 Suppl 5:v1–v49.PubMedCrossRef
2.
go back to reference Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64(6):628–34.PubMedCrossRef Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64(6):628–34.PubMedCrossRef
3.
go back to reference Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.PubMedCrossRef Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.PubMedCrossRef
4.
go back to reference Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8.CrossRef Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8.CrossRef
5.
go back to reference Bozdag S, Li A, Riddick G, et al. Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels. PLoS One. 2013;8(4):e62982.PubMedCrossRef Bozdag S, Li A, Riddick G, et al. Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels. PLoS One. 2013;8(4):e62982.PubMedCrossRef
6.
go back to reference Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer cell. 2010;17(5):510–22.PubMedCrossRef Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer cell. 2010;17(5):510–22.PubMedCrossRef
7.
go back to reference Wiestler B, Claus R, Hartlieb SA, et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-oncology. Apr 17 2013. Wiestler B, Claus R, Hartlieb SA, et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-oncology. Apr 17 2013.
8.
go back to reference Curran Jr WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Ins. 1993;85(9):704–10.CrossRef Curran Jr WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Ins. 1993;85(9):704–10.CrossRef
9.
go back to reference • Scott JG, Bauchet L, Fraum TJ, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer. 2012;118(22):5595–600. This paper reports a new prognostic scheme for patients with glioblastoma 70 years of age and older.PubMedCrossRef • Scott JG, Bauchet L, Fraum TJ, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer. 2012;118(22):5595–600. This paper reports a new prognostic scheme for patients with glioblastoma 70 years of age and older.PubMedCrossRef
10.
go back to reference Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien). 2003;145(1):5–10.CrossRef Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien). 2003;145(1):5–10.CrossRef
11.
go back to reference McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156–62.PubMedCrossRef McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156–62.PubMedCrossRef
12.
go back to reference Kita D, Ciernik IF, Vaccarella S, et al. Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology. 2009;33(1):17–22.PubMedCrossRef Kita D, Ciernik IF, Vaccarella S, et al. Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology. 2009;33(1):17–22.PubMedCrossRef
13.
go back to reference Walker MD, Alexander Jr E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49(3):333–43.PubMedCrossRef Walker MD, Alexander Jr E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49(3):333–43.PubMedCrossRef
14.
go back to reference Paszat L, Laperriere N, Groome P, Schulze K, Mackillop W, Holowaty E. A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;51(1):100–7.PubMedCrossRef Paszat L, Laperriere N, Groome P, Schulze K, Mackillop W, Holowaty E. A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;51(1):100–7.PubMedCrossRef
15.
go back to reference Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527–35.PubMedCrossRef Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527–35.PubMedCrossRef
16.
go back to reference Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(9):1583–8.CrossRef Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(9):1583–8.CrossRef
17.
go back to reference •• Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncology. 2012;13(9):916–26. Randomized phase 3 trial comparing 2 different radiation schedules and temozolomide and showing that the 6-week course of radiotherapy, which is considered standard for younger patients, may be associated with lower survival in older patients.PubMedCrossRef •• Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncology. 2012;13(9):916–26. Randomized phase 3 trial comparing 2 different radiation schedules and temozolomide and showing that the 6-week course of radiotherapy, which is considered standard for younger patients, may be associated with lower survival in older patients.PubMedCrossRef
18.
go back to reference DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39(6):789–96.PubMedCrossRef DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39(6):789–96.PubMedCrossRef
19.
go back to reference Nayak L, Iwamoto FM. Primary brain tumors in the elderly. Curr Neurol Neurosci Rep. 2010;10(4):252–8.PubMedCrossRef Nayak L, Iwamoto FM. Primary brain tumors in the elderly. Curr Neurol Neurosci Rep. 2010;10(4):252–8.PubMedCrossRef
20.
go back to reference Iwamoto FM, Cooper AR, Reiner AS, Nayak L, Abrey LE. Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997–2007). Cancer. 2009;115(16):3758–66.PubMedCrossRef Iwamoto FM, Cooper AR, Reiner AS, Nayak L, Abrey LE. Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997–2007). Cancer. 2009;115(16):3758–66.PubMedCrossRef
21.
go back to reference Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology. 2009;10(5):459–66.PubMedCrossRef Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology. 2009;10(5):459–66.PubMedCrossRef
22.
go back to reference Brandes AA, Vastola F, Basso U, et al. A prospective study on glioblastoma in the elderly. Cancer. 2003;97(3):657–62.PubMedCrossRef Brandes AA, Vastola F, Basso U, et al. A prospective study on glioblastoma in the elderly. Cancer. 2003;97(3):657–62.PubMedCrossRef
23.
go back to reference Minniti G, De Sanctis V, Muni R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008;88(1):97–103.PubMedCrossRef Minniti G, De Sanctis V, Muni R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008;88(1):97–103.PubMedCrossRef
24.
go back to reference Barker CA, Chang M, Chou JF, et al. Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neurooncol. 2012;109(2):391–7.PubMedCrossRef Barker CA, Chang M, Chou JF, et al. Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neurooncol. 2012;109(2):391–7.PubMedCrossRef
25.
go back to reference •• Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology. 2012;13(7):707–15. Phase III trial showing non-inferiority of temozolomide compared to standard radiotherapy in older patients with malignant astrocytomas.PubMedCrossRef •• Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology. 2012;13(7):707–15. Phase III trial showing non-inferiority of temozolomide compared to standard radiotherapy in older patients with malignant astrocytomas.PubMedCrossRef
26.
go back to reference Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(5):740–5.CrossRef Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(5):740–5.CrossRef
27.
go back to reference Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(28):4733–40.CrossRef Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(28):4733–40.CrossRef
28.
go back to reference Wu W, Lamborn KR, Buckner JC, et al. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro-Oncology. 2010;12(2):164–72.PubMedCrossRef Wu W, Lamborn KR, Buckner JC, et al. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro-Oncology. 2010;12(2):164–72.PubMedCrossRef
29.
go back to reference Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72(14):1217–22.PubMedCrossRef Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72(14):1217–22.PubMedCrossRef
30.
go back to reference Niiro M, Yatsushiro K, Nakamura K, Kawahara Y, Kuratsu J. Natural history of elderly patients with asymptomatic meningiomas. J Neurol Neurosurg Psychiatry. 2000;68(1):25–8.PubMedCrossRef Niiro M, Yatsushiro K, Nakamura K, Kawahara Y, Kuratsu J. Natural history of elderly patients with asymptomatic meningiomas. J Neurol Neurosurg Psychiatry. 2000;68(1):25–8.PubMedCrossRef
31.
go back to reference Oya S, Kim SH, Sade B, Lee JH. The natural history of intracranial meningiomas. J Neurosurg. 2011;114(5):1250–6.PubMed Oya S, Kim SH, Sade B, Lee JH. The natural history of intracranial meningiomas. J Neurosurg. 2011;114(5):1250–6.PubMed
32.
go back to reference Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109(1):187–93.PubMedCrossRef Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109(1):187–93.PubMedCrossRef
33.
go back to reference Kaley TJ, Wen PY, Schiff D, et al. Phase Ii Trial of Sunitinib (Su011248) for Recurrent Meningioma. Neuro-Oncology. 2010;12:75–6. Kaley TJ, Wen PY, Schiff D, et al. Phase Ii Trial of Sunitinib (Su011248) for Recurrent Meningioma. Neuro-Oncology. 2010;12:75–6.
Metadata
Title
Primary Central Nervous System Tumors in the Aging Population
Author
Fabio M. Iwamoto
Publication date
01-09-2013
Publisher
Springer US
Published in
Current Geriatrics Reports / Issue 3/2013
Electronic ISSN: 2196-7865
DOI
https://doi.org/10.1007/s13670-013-0055-4

Other articles of this Issue 3/2013

Current Geriatrics Reports 3/2013 Go to the issue

Infectious Diseases in the Elderly (SF Bradley, Section Editor)

Issues Surrounding Antibiotic Use in Older Adults

Infectious Diseases in the Elderly (SF Bradley, Section Editor)

The Epidemiology and Clinical Impact of Surgical Site Infections in the Older Adult

Infectious Diseases in the Elderly (SF Bradley, Section Editor)

Issues in the Diagnosis and Management of Urinary Tract Infections in the Older Adult

Infectious Diseases in the Elderly (SF Bradley, Section Editor)

Emergence and Control of Antibiotic-resistant Gram-negative Bacilli in Older Adults

Neurology of Aging (KS Marder, Section Editor)

Vascular Dementia

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine